| Literature DB >> 22640398 |
G Craig Wood1, Xin Chu, Christina Manney, William Strodel, Anthony Petrick, Jon Gabrielsen, Jamie Seiler, David Carey, George Argyropoulos, Peter Benotti, Christopher D Still, Glenn S Gerhard.
Abstract
BACKGROUND: The effectiveness of weight loss therapies is commonly measured using body mass index and other obesity-related variables. Although these data are often stored in electronic health records (EHRs) and potentially very accessible, few studies on obesity and weight loss have used data derived from EHRs. We developed processes for obtaining data from the EHR in order to construct a database on patients undergoing Roux-en-Y gastric bypass (RYGB) surgery.Entities:
Mesh:
Year: 2012 PMID: 22640398 PMCID: PMC3508953 DOI: 10.1186/1472-6947-12-45
Source DB: PubMed Journal: BMC Med Inform Decis Mak ISSN: 1472-6947 Impact factor: 2.796
Figure 1Flow diagram of data used to generate research database.
Demographic data (n=2028)
| Gender | | |
| | Male, n (%) | 385 (19%) |
| | Female, n (%) | 1643 (81%) |
| Age | | |
| | Median [range] | 46 [18, 72] |
| Race | | |
| | White/Caucasian, n (%) | 1960 (97%) |
| | Black, n (%) | 44 (2%) |
| | Other, n (%) | 24 (1%) |
| Smoking | | |
| | Current, n (%) | 204 (11%) |
| | Quit, n (%) | 711 (38%) |
| | Never, n (%) | 948 (51%) |
| | Not known, n (%) | 165 (8%) |
| Any alcohol use | | |
| | Yes, n (%) | 729 (41%) |
| | No, n (%) | 1029 (59%) |
| | Not known, n (%) | 270 (13%) |
| Height (inches) | | |
| | Mean (SD) | 65.5 (3.4) |
| | Median [range] | 65.0 [54.8, 78.0] |
| Weight (pounds) | | |
| | Mean (SD) | 303 (64) |
| | Median [range] | 292 [180, 614] |
| BMI (kg/m2) | | |
| | Mean (SD) | 49.6 (8.8) |
| | Median [range] | 47.9 [32.5, 94.3] |
| Waist circumference | | |
| | Mean (SD) | 53.5 (6.5) |
| Median [range] | 52.8 [39.0, 76.0] |
Frequency of common co-morbidities (N=2028)
| Hypertension | 1147 (57%) |
| Hypercholesterolemia | 881 (43%) |
| Diabetes | 838 (41%) |
| Sleep disturbances | 737 (36%) |
| Depression | 717 (35%) |
| Diseases of esophagus | 637 (31%) |
| Osteoarthrosis | 534 (26%) |
| Hypothyroidism | 369 (18%) |
| Asthma | 314 (15%) |
Use of common medication subclasses (N=2028)
| Biguanides | 817 (40%) |
| Proton Pump Inhibitors | 765 (38%) |
| NSAIDs | 765 (38%) |
| SSRIs | 698 (34%) |
| HMG CoA Reductase Inhibitors | 661 (33%) |
| Opioid Combinations | 567 (28%) |
| Salicylates | 533 (26%) |
| ACE Inhibitors | 532 (26%) |
| Beta Blockers Cardio-Selective | 516 (25%) |
| Sympathomimetics | 503 (25%) |
| Loop Diuretics | 452 (22%) |
| Thyroid Hormones | 407 (20%) |
| Insulin | 298 (15%) |
| Thiazides and Thiazide-Like Diuretics | 295 (15%) |
| Antihypertensive Combinations | 263 (13%) |
| Insulin Sensitizing Agents | 258 (13%) |
| Sulfonylureas | 253 (13%) |
Availability of common laboratory test results (N=2028)
| Glucose | 99% | 92% |
| BUN | 99% | 92% |
| Sodium | 99% | 92% |
| Potassium | 99% | 92% |
| Chloride | 99% | 92% |
| CO2 | 99% | 92% |
| Creatinine | 99% | 92% |
| Calcium | 99% | 92% |
| WBC | 99% | 90% |
| RBC | 99% | 90% |
| Hemoglobin | 99% | 90% |
| Hematocrit | 99% | 90% |
| MCV | 99% | 90% |
| MCH | 99% | 90% |
| MCHC | 99% | 90% |
| RDW | 99% | 90% |
| Platelet count | 99% | 90% |
| MPV | 99% | 90% |
| ALT | 99% | 69% |
| AST | 99% | 69% |
| Alkaline phosphate | 99% | 69% |
| Total Bilirubin | 99% | 69% |
| GFR (estimated) | 98% | 92% |
| TSH | 98% | 37% |
| Triglycerides | 98% | 41% |
| Cholesterol | 98% | 43% |
| HDL | 98% | 41% |
| LDL | 97% | 44% |
| HbA1c | 96% | 42% |
| Insulin | 95% | 14% |
| Ferritin | 88% | 52% |
| Iron | 88% | 50% |
| Iron Binding Capacity | 88% | 48% |
| Transferrin Saturation | 88% | 45% |
| Anion Gap | 87% | 91% |
| PTH | 83% | 71% |
| Folic Acid | 68% | 23% |
Figure 2Kaplan-Meier curves of length of follow-up (N = 2028). The plots are based upon a sample size of 174 patients with 3255 weight measurements for initial BMI of 35–39 kg/m2, 1032 patients with 20,284 weight measurements for initial BMI of 40–49 kg/m2, and 822 patients with 16,226 weight measurements for BMI of 50+ kg/m2.